Probiotics (Lactobacillus & Bifidobacterium)

📜 Historical Use

Probiotics reached mainstream American use recently and fast. NCCIH cites the 2012 National Health Interview Survey, in which about 4 million U.S. adults - 1.6 percent - had used probiotics or prebiotics in the previous 30 days, making them the third most commonly used dietary supplement other than vitamins and minerals. Adult use had quadrupled between 2007 and 2012. The scientific scaffolding arrived alongside the commercial one: the Human Microbiome Project, which ran from 2007 to 2016, mapped the normal bacteria that live in and on the healthy human body, and it is that catalogue that lets researchers investigate links between changes in the microbiome and particular diseases. NCCIH describes probiotics as reaching consumers through "yogurt and other fermented foods, dietary supplements, and beauty products." Regulation has not kept pace with the category. NCCIH calls government regulation of probiotics in the United States "complex": depending on a product's intended use, the FDA may treat it as a dietary supplement, a food ingredient, or a drug. Supplements need no FDA approval before they are marketed and may make claims about how the product affects the structure or function of the body, but may not claim to lower disease risk without FDA consent. Only a probiotic marketed as a drug must be proven safe and effective in clinical trials and approved before sale.

📊 What the Research Shows

The evidence is far more uneven than the supplement aisle suggests, and it is weakest on the use this page has historically led with. On irritable bowel syndrome, NCCIH reports that "it was not possible to draw definite conclusions about their effectiveness or to identify which species, strains, or combinations of probiotics are most likely to be helpful." Nothing in the federal monograph supports a percentage reduction in IBS symptoms or in bloating. Where the evidence is strongest it is mostly about diarrhoea. A 2017 review of 3,631 non-hospitalised participants found that giving probiotics alongside antibiotics "was associated with a decrease of about half in the likelihood of antibiotic-associated diarrhea," and a 2017 analysis of 31 studies and 8,672 patients left reviewers "moderately certain that probiotics can reduce the risk of C. difficile diarrhea in adults and children." Benefit also appears for necrotizing enterocolitis in very-low-birth-weight infants (2017 review, 7,325 infants), for sepsis in premature infants (37 studies, 9,416 participants), for infant colic in exclusively breastfed babies given Lactobacillus reuteri DSM 17938 (2018 review, 471 participants), and for constipation in older adults, where the benefit was "small but meaningful" (2017, 778 participants). Against that, reviewers "did not find evidence" of benefit in Crohn's disease, in constipation in children, or in urinary tract infections; benefit "has not been demonstrated" for antibiotic-associated diarrhoea in elderly people; and guidelines find "insufficient evidence" for traveller's diarrhoea. Acne, asthma and dental caries were inconclusive or rated low quality.

Take 10-50 billion CFU daily with food. Look for multi-strain formulas with delayed-release capsules. Store refrigerated.

Start low (10B CFU) to avoid die-off symptoms. Avoid if severely immunocompromised.

⚠️ What happens if taken in excess:

Generally very safe, but excessive supplementation (>100 billion CFU/day) may cause severe bloating, gas, and diarrhea from die-off reactions. In immunocompromised individuals, high-dose probiotics can rarely cause bacteremia (bacteria entering the bloodstream) or fungemia, which can be life-threatening. D-lactic acidosis has been reported with very high doses in some individuals.

This is a section where accuracy matters more than a long list. The NCCIH monograph read for this entry documents no named drug interactions at all: no cytochrome P450 effects, and none of the warfarin or cyclosporine warnings that attach to botanicals such as St John's wort or ginkgo. That absence is not evidence of safety. It reflects two things: probiotics are live organisms rather than absorbed plant chemicals, so the pharmacokinetic framework that governs herbal extracts largely does not apply, and the interaction question simply has not been studied for probiotics the way it has for herbs. What the monograph does document is drug-relevant in a different way. It names the "transfer of antibiotic resistance genes from probiotic microorganisms to other microorganisms in the digestive tract" as a recognised risk, which is a concern about whether a future course of antibiotics will work rather than about any pill taken today. And it states that harm is likelier "in people with severe illnesses or compromised immune systems" - precisely the group for whom a deliberately swallowed live culture becomes a plausible source of bloodstream infection. Anyone on immunosuppressive medication, anyone being treated for cancer, and anyone who is critically ill should therefore treat a probiotic as a clinical decision rather than a grocery one, and should have it checked against a current drug interaction database rather than against this page.

1. Probiotics: Usefulness and Safety — National Center for Complementary and Integrative Health NCCIH, U.S. National Institutes of Health (2019)[NIH ↗]